[Experimental and clinical studies of sulbactam/cefoperazone in pediatric field].

Abstract

Clinical trials were carried out with sulbactam/cefoperazone (SBT/CPZ) (combination ratio of 1:1) in pediatric infections. Results were as follows. The mean half-lives of SBT and CPZ in the serum following intravenous injection of SBT/CPZ were about 0.7 and 1.2 hours, respectively. Urinary excretions of SBT and CPZ within 6 hours after intravenous injection of SBT/CPZ were 81.9% and 28.1%, respectively. SBT/CPZ was administered to 33 pediatric patients with various infection; 18 respiratory tract infections, 12 urinary tract infections and 3 Salmonella enterocolitis. The overall efficacy rate was 87.9%. In particular, 7 of 8 urinary tract infections caused by beta-lactamase producing organisms were improved after administration of SBT/CPZ. Diarrhea in 8 and soft stool in 3 of 33 patients occurred, and slight elevation of GOT/GPT was observed in 2 patients.

• Authors: T Nakashima, S Ueda, F Hayakawa, Y Miyachi, S Hakamada, K Kuno
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 37 Issue 10 Pg. 1846-58 (Oct 1984) ISSN: 0368-2781 [Print] Japan
• PMID: 6094864 (Publication Type: English Abstract, Journal Article)

Chemical References

• Drug Combinations
• beta-Lactamase Inhibitors
• Cefoperazone
• Penicillanic Acid
• Sulbactam

Topics

• Adolescent
• Age Factors
• Bacteria (drug effects)
• Bacterial Infections (drug therapy, microbiology)
• Cefoperazone (administration & dosage, metabolism, pharmacology)
• Child
• Child, Preschool
• Drug Combinations
• Drug Evaluation
• Drug Resistance, Microbial
• Female
• Half-Life
• Humans
• Infant
• Male
• Penicillanic Acid (administration & dosage, metabolism, pharmacology)
• Sulbactam
• beta-Lactamase Inhibitors